Zacks Research Issues Positive Estimate for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Analysts at Zacks Research upped their Q1 2025 earnings per share estimates for shares of Sanofi in a research note issued to investors on Wednesday, January 22nd. Zacks Research analyst K. Shah now anticipates that the company will post earnings of $0.85 per share for the quarter, up from their previous estimate of $0.84. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi’s Q2 2025 earnings at $0.94 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $4.47 EPS and Q3 2026 earnings at $1.47 EPS.

Separately, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Sanofi Trading Down 0.7 %

Shares of Sanofi stock opened at $52.97 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The business has a fifty day simple moving average of $48.90 and a two-hundred day simple moving average of $52.22. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a market capitalization of $134.43 billion, a price-to-earnings ratio of 27.03, a P/E/G ratio of 1.19 and a beta of 0.57.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SNY. Stablepoint Partners LLC raised its position in shares of Sanofi by 0.8% in the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after buying an additional 189 shares in the last quarter. Abel Hall LLC raised its holdings in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after acquiring an additional 194 shares in the last quarter. PDS Planning Inc lifted its position in shares of Sanofi by 3.1% during the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after acquiring an additional 200 shares during the period. Eagle Ridge Investment Management grew its holdings in shares of Sanofi by 3.8% during the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock worth $321,000 after purchasing an additional 203 shares in the last quarter. Finally, Financial Advocates Investment Management increased its position in shares of Sanofi by 3.4% in the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after purchasing an additional 206 shares during the period. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.